REFERENCES
- Quaglio G, Lugoboni F, Fornasiero A, Lechi A, Gerra G, Mezzelani P. Dependence on zolpidem: Two case reports of detoxification with flumazenil infusion. Int Clin Psychopharmacol. 2005; 20: 285–287
- Liappas I A, Malitas P N, Dimopoulos N P, et al. Zolpidem dependence case series: Possible neurobiological mechanisms and clinical management. J Psychopharmacol. 2003; 17: 131–135
- Pritchett D B, Sontheimer H, Shivers B D, et al. Importance of novel GABAA receptor subunit for benzodiazepine pharmacology. Nature. 1989; 338: 582–585
- McKernan R M, Rosahl T W, Reynolds D S, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000; 3: 587–592
- Löw K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000; 290: 131–134
- Göder R, Treskov V, Burmester J, Aldenhoff J B, Hinze-Selch D. Zolpidem: The risk of tolerance and dependence according to case reports, systematic studies and recent molecular biological data. Fortschr Neurol Psychiatr. 2001; 69: 592–596, [in German]
- Mirza N R, Nielsen E Ø. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?. J Pharmacol Exp Ther. 2006; 316: 1378–1385
- Tripodianakis J, Potagas C, Papageorgiou P, Lazaridou M, Matikas N. Zolpidem-related epileptic seizures: A case report. Eur Psychiatry. 2003; 18: 140–141
- Cubała W J, Landowski J. Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 539–540
- Madrak L N, Rosenberg M. Zolpidem abuse. Am J Psychiatry. 2001; 158: 1330–1331